GLP-1 · GIP · Glucagon

Retatrutide in Canada

Also known as LY3437943 · GGG tri-agonist · Triple agonist retatrutide · GIP/GLP-1/glucagon receptor agonist

Retatrutide is an investigational peptide from Eli Lilly that activates three metabolic receptors — GIP, GLP-1 and glucagon — on a single backbone. It is the first triple agonist to reach Phase 3, with a 2023 Phase 2 trial reporting the largest body-weight change yet seen with an incretin peptide, and it is not approved by any regulator anywhere. Canada Peptides carries research-grade retatrutide in 10, 15, 20 and 30 mg vials and a 15 mg reloadable pen, priced and shipped in CAD for laboratory and research use only.

Quick facts

Class: Acylated GIP / GLP-1 / glucagon receptor triple agonist (investigational)
Structure: 39 amino acids on a GIP-derived backbone · Aib substitutions · Lys17 acylated with a C20 diacid via a linker · ~4,731 Da
Half-life: Approximately 6 days after subcutaneous injection (Phase 1 data)
Route in research: Subcutaneous once weekly in all Phase 2 and Phase 3 protocols
Cadence in research: Once weekly; escalated every 4 weeks in trials from 1–2 mg toward 8–12 mg
Storage: Lyophilised: refrigerated, dark. Reconstituted or loaded pen: refrigerated, used within about 30 days
Status in Canada: No Health Canada market authorisation or DIN; investigational everywhere. Research use only

Retatrutide FAQ

Is retatrutide for sale in Canada?

Yes. Research-grade retatrutide is available in Canada from Canada Peptides in five formats — 10 mg, 15 mg, 20 mg and 30 mg vials and a 15 mg reloadable pen — priced and shipped in CAD. It is supplied strictly for laboratory and research use, not for human consumption. There is no approved retatrutide medicine anywhere.

What is retatrutide?

Retatrutide is an investigational 39-amino-acid peptide from Eli Lilly that activates the GIP, GLP-1 and glucagon receptors on a single backbone. It is the first triple agonist to reach Phase 3, and the glucagon arm is what distinguishes it from dual agonists such as tirzepatide.

What does the research on retatrutide show?

A Phase 2 obesity trial published in 2023 reported mean weight change of −24.2% at 48 weeks in the 12 mg group versus −2.1% with placebo, and a Phase 2 diabetes trial reported HbA1c reductions. Phase 3 TRIUMPH trials are ongoing, with the sponsor releasing topline results but no peer-reviewed Phase 3 publication yet.

What is the half-life of retatrutide?

Approximately six days after subcutaneous injection, according to Phase 1 data, which is why every trial has used once-weekly administration. Steady state is reached after four to five weekly doses.

How was retatrutide dosed in studies?

The Phase 2 obesity trial used 1, 4, 8 or 12 mg once weekly, with the higher arms starting at 2 or 4 mg and escalating every four weeks. There is no validated or approved human dose; this page does not recommend one, and the material sold here is for research use only.

What side effects does retatrutide research report?

Mostly gastrointestinal, dose-related and concentrated during escalation. A dose-dependent rise in heart rate that peaked around 24 weeks, and skin sensation changes (hyperaesthesia, dysaesthesia) in a minority of participants, are features noted specifically for retatrutide. Long-term safety data do not yet exist.

Is retatrutide legal in Canada?

Retatrutide is not a controlled substance, but it has no Health Canada approval, no DIN and no approval from any other regulator. It may be sold for laboratory research, which is how it is sold here. It falls under WADA's S0 category and is prohibited for tested athletes at all times.

Retatrutide vs tirzepatide vs semaglutide — what is the difference?

Receptor coverage and evidence depth. Semaglutide activates GLP-1 only and has the deepest evidence; tirzepatide adds GIP and is approved; retatrutide adds GIP and glucagon and is still investigational, with the largest Phase 2 effect size and the shortest safety record.

Retatrutide in Canada

Quick facts

Retatrutide — for sale in Canada

Watch: retatrutide explained

What is Retatrutide?

Evidence at a glance

Pharmacology

Identity and chemistry

Storage and stability

Research indications

Research protocols

Interactions and stacking in research

Reconstitution and handling

Side effects and safety signals

Regulatory status in Canada

Further reading

Retatrutide FAQ

Research references